Hopes rise for a new treatment option for people living with lupus, after UCB and Biogen reveal phase 3 data with their anti-CD40L antibody DZP.

(The Masters does not extend invitations to winners of Additional Events.) NOTE: Until all methods of entry are released by the governing bodies, traditional criteria are used to determine qualifiers.